Pterjiyum tedavisinde intraoperatif anti-vegf kullanımı: Bevacizumab ile mitomisin-c uygulamasının karşılaştırmalı çalışması / Pterji̇yum tedavi̇si̇nde i̇ntraoperati̇f anti̇-vegf kullanimi: Bevaci̇zumab i̇le mi̇tomi̇si̇n-c uygulamasinin karşilaştirmali çalişmasi
Üst veriTüm öğe kaydını göster
In this study, it was aimed to compare the effects on the recurrence rates of primary excision surgery together with Mitomisin-C or Anti-VEGF usage on patients that were diagnosed primary pterygium at our clinic. 30 eyes of 30 patients that came and were diagnosed primary pterygium between July 2007 and April 2008 at our clinic were included to the study. Patients that have been diagnosed any ocular disease like glaucoma, vitreoretinal disease or dry eye syndrome and using any ocular medications were excluded from the study. The cases were randomly divided into two equal groups, 15 eyes of 15 patients that were included in the first group were undergone primary excision surgery with intraoperative 0,2 mg/ml Mitomycin-C usage and the other 15 eyes of 15 patients that were included in the second group were undergone primary excision surgery with subconjunctival 2,5mg/0,1ml Bevacizumab (Avastin®, Altuzan®) injection. The patients were examined 1.day, 1.week, 1.month, 3.month, 6.month and 1.year after the surgery. During these examinations, the cases with recurrence and time of recurrence were recorded. The recurrence rates were calculated and statistically compared according to the demographic and clinical properties and the type of surgery that was performed. Statistically homogeneity of two groups was established for age, sexuality and side of the affected eyes (p=0,967-1,00-0,439). The average of follow-up time was 13,9±4,3 months. Any complications were not seen in MMC group, but in BVCZMB group; contraction of wound was seen in 2 patients and suture reaction was seen in 1 patient. Recurrence was seen in 4 patients (%26,7) in MMC group while it was seen in 10 patients (%66,7) in BVCZMB group. The average age of the patients that were seen recurrence in the BVCZMB group was statistically low (p=0,007). When the groups were evaluated separately, there was not seen any statistically meaningful difference between the sexuality and the recurrence rates (p=0,235-0,58). The average time of recurrence was 2,5±0,9 months in MMC group while it was 3,6±1,2 months in BVCZMB group. As a result; primary excision + subconjunctival bevacizumab (PE+BVCZMB) injection does not supply any advantage for recurrence in a longtime period, however it should not be forgetten that PE + BVCZMB can be a preferred method for older patients to clear off the serious complications of PE + MMC method.